Research programme: antibody-drug conjugates - ABL Bio/LegoChem Biosciences

Drug Profile

Research programme: antibody-drug conjugates - ABL Bio/LegoChem Biosciences

Alternative Names: ABL 201; ABL 202; LCB14-XXXX - ABL Bio/LegoChem Biosciences

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ABL Bio
  • Developer ABL Bio; LegoChem Biosciences
  • Class Antibodies; Antineoplastics; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Solid tumours

Most Recent Events

  • 17 Apr 2017 LegoChem Biosciences has patent protection for ConjuAll™ technology in USA
  • 15 Mar 2017 Early research in Mantle cell lymphoma in South Korea (Parenteral)
  • 06 Mar 2017 Early research in Chronic lymphocytic leukaemia in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top